Nutr Res Pract.  2007 Dec;1(4):298-304.

Effect of Coenzyme Q10 and green tea on plasma and liver lipids, platelet aggregation, TBARS production and erythrocyte Na leak in simvastatin treated hypercholesterolmic rats

• Kim YH
• Moon YI
• Kang YH
• Kang JS

Abstract

This study was conducted to investigate the hypocholesterolemic effect of simvastatin (30 mg/kg BW) and antioxidant effect of coenzyme Q10 (CoQ10, 15 mg/kg BW) or green tea (5%) on erythrocyte Na leak, platelet aggregation and TBARS production in hypercholesterolemic rats treated with statin. Food efficiency ratio (FER, ADG/ADFI) was decreased in statin group and increased in green tea group, and the difference between these two groups was significant (p<0.05). Plasma total cholesterol was somewhat increased in all groups with statin compared with control. Plasma triglyceride was decreased in statin group and increased in groups of CoQ10 and green tea, and the difference between groups of statin and green tea was significant (p<0.05). Liver total cholesterol was not different between the control and statin group, but was significantly decreased in the group with green tea compared with other groups (p<0.05). Liver triglyceride was decreased in groups of statin and green tea compared with the control, and the difference between groups of the control and green tea was significant (p<0.05). Platelet aggregation of both the initial slope and the maximum was not significantly different, but the group with green tea tended to be higher in initial slope and lower in the maximum. Intracellular Na of group with green tea was significantly higher than the control or statin group (p<0.05). Na leak in intact cells was significantly decreased in the statin group compared with the control (p<0.05). Na leak in AAPH treated cells was also significantly reduced in the statin group compared with groups of the control and CoQ10 (p<0.05). TBARS production in platelet rich plasma was significantly decreased in the groups with CoQ10 and green tea compared with the control and statin groups (p<0.05). TBARS of liver was significantly decreased in the group with green tea compared with the statin group (p<0.05). In the present study, even a high dose of statin did not show a cholesterol lowering effect, therefore depletion of CoQ10 following statin treatment in rats is not clear. More clinical studies are needed for therapeutic use of CoQ10 as an antioxidant in prevention of degenerative diseases independent of statin therapy.

Keyword

Simvastatin; CoQ10; cholesterol; erythrocyte Na leak; platelet aggregation; TBARS production

MeSH Terms

Animals
Antioxidants
Blood Platelets*
Cholesterol
Erythrocytes*
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Liver*
Plasma*
Platelet Aggregation*
Platelet-Rich Plasma
Rats*
Simvastatin*
Tea*
Thiobarbituric Acid Reactive Substances*
Triglycerides
Antioxidants
Cholesterol
Simvastatin
Tea
Thiobarbituric Acid Reactive Substances

Figure

• 

  Fig. 1 Microscopic appearance of liver tissue (×400)

Reference

1. Aggarwal D, West KL, Zern TL, Shrestha S, Fernandez ML. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord. 2005. 5:30.

2. Akiba T, Shibuta T, Amano Y, Koga T, Takimoto M. 28-day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats. J Toxicol Sci. 1999. 23:701–711.

3. Bandoh T, Mitani H, Niihashi M, Totsuka T, Sakurai I, Hayashi S. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol. 2000. 35:136–144.

4. Broncel M, Koter-Michalak M, Chojnowska-Jezierska J. The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006. 63:738–742.

5. Broncel M, Balcerak M, Sikora J, Chojnowska-Jezierska J. Effect of fluvastatin extended release on the protein-lipid structure of erythrocyte membrane and C-reactive protein in patients with hyperlipidemia. Polski merkuriusz lekarski. 2007. 22:107–111.

6. Dajani EZ, Shahwan TG, Dajani NE. Statins, platelet aggregation and coronary heart disease. J Assoc Acad Minor Phys. 2002. 13:27–31.

7. Davis HR Jr, Pula KK, Burrier RE, Watkins RW. The synergistic hypocholesterolemic activity of the potent cholesterolabsorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism. 2001. 50:1234–1241.

8. Dhanasekaran M, Ren J. The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. Curr Neurovasc Res. 2005. 2:447–459.

9. Dietscht JM, Turley SD, Spady DK. Role of the liver in the maintenance of cholesterol and low density lipoprotein in homeostasis in different animal species including human. J Lipid Res. 1993. 34:1637–1659.

10. Draper HH, Callant AS. A simplified hemolysis test for vitamin E deficiency. J Nutr. 1969. 98:390–394.

11. Famer D, Crisby M. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet. Neurosci Lett. 2007. 419:68–73.

12. Fernandez ML. Guinea pigs as models for cholesterol and lipoprotein metabolism. J Nutr. 2001. 131:10–20.

13. Folch J, Lee M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957. 226:497–509.

14. Galus R, Włodarski P, Włodarski K. Influence of fluvastatin on bone formation induced by demineralized bone matrix in mice. Pharmacol Rep. 2006. 58:443–447.

15. Haramaki N, Ikeda H, Takenaka K, Matsuoka H, Imaizumi T. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol. 2007. 27:1471–1477.

16. Kaneta S, Satoh K, Kanda M, Ichihara K. All hydrophobic HMG coA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cell. Atherosclerosis. 2003. 170:237–243.

17. Kang JS, Cregor MD, Smith JB. Effect of calcium on blood pressure, platelet aggregation and erythrocyte sodium transport in Dahl salt-sensitive rats. J Hypertens. 1990. 8:245–250.

18. King DE, Mainous AG, Player A, Geesey ME. Use of statins and blood pressure. Am J Hypertens. 2007. 20:937–941.

19. Lamperti C, Naini AB, Lucchini V, Moggio M, Sciacco M, Kaufmann P, DiMauro S. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005. 62:1709–1712.

20. Lankas GR, Cukierski MA, Wise LD. The role of maternal toxicity in lovastatin-induced developmental toxicity. Birth Defects Res B Dev Reprod Toxicol. 2004. 71:111–123.

21. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007. 7:S168–S174.

22. Liu CH, Huang MT, Huang PC. Source of triglyceride accumulation in livers of rats fed a cholesterol supplemented diet. Lipids. 1995. 30:527–531.

23. Mabuchi H, Higashikata T, Kawashiri M, Inazu A, Koizumi J, Kobayashi J. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb. 2005. 12:111–119.

24. Mabuchi H, Nohara A, Katsuda S, Inatsuda S, Koizumi J. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. 2007. 195:e182–e189.

25. Maridonneau I, Braquet P, Garay RP. Na+ and K+ transport damage induced by oxygen free radicals in human red blood cell membranes. Biol Chem. 1983. 285:3107–3113.

26. Mason RP, Walter MF, Day CA, Jacob RF. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem. 2006. 281:9337–9345.

27. Matsuno H, Takei M, Hayashi H, Nakajima K, Kozawa O. Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol. 2004. 43:333–340.

28. Mitane Y, Miwa Sagesaka M, Okada S. Platelet aggregation inhibitors in hot water extract of green tea. Chem Pharm Bull. 1990. 38:790–793.

29. Naseem KM, Bruckdorfer KR. The influence of organic peroxides on platelet aggregation and sensitivity to nitric oxide. Platelets. 1999. 10:146–152.

30. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005. 13:76–79.

31. Osada K, Takahashi M, Hoshina S, Nakamura S, Sugano M. Tea catechins inhibit cholesterol oxidation accompanying oxidation of low density lipoprotein in vitro. Comp Biochem Physiol C Toxicol Pharmacol. 2001. 128:153–164.

32. Pentaceska SS, DeRosa S, Olm V, Diaz N, Pappolla M, Refolo LM. Statin therapy for alzheimer' disease; will it work? J Mol Neurosci. 2002. 19:155–161.

33. Raederstorff DG, Schlachter MF, Elste V, Weber P. Effect of EGCG on lipid absorption and plasma lipid levels in rats. J Nutr Biochem. 2003. 14:326–332.

34. Ryszawa N, Kawczyńska-Drózdz A, Adamek-Guzik T, Korbut R, Guzik TJ. Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. J Physiol Pharmacol. 2006. 57:611–626.

35. Saffari Y, Sadrzadeh SM. Green tea metabolite EGCG protects membranes against oxidative damage in vitro. Life Sci. 2004. 74:1513–1518.

36. Sawada M, Matsuo M, Seki J. Inhibition of cholesterol synthesis causes both hypercholesterolemia and hypocholesterolemia in hamsters. Biol Pharm Bull. 2002. 25:1577–1582.

37. Sayama K, Lin SX, Zheng GD, Oguni I. Antiobee effects of green tea powder and its components. International Symposium on Green tea. 2003. 7:In : KFN Conference; 55–62.

38. Staal A, Frith JC, Fewnch MH, Stuwartz J, Rogers MJ, Feyen JH. The ability of statins to inhibit bone reabsorption is directly related to their inhibitory effect on HMG coA reductase activity. J Bone Miner Res. 2003. 18:88–96.

39. Susic D, Varagic J, Ahn J, slama M, Frohlich ED. Beneficial pleitropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 2003. 42:1091–1097.

40. Tavintharan S, Ong CN, Sivakumar M, Lim SC, Sum CF. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol. 2007. 223:173–179.

41. Terao J, Piskula M, Yao Q. Protective effect of epicatechin, epicatechin gallate, and quercetin on lipid peroxidation in phospholipid bilayers. Arch Biochem Biophys. 1994. 308:278–284.

42. Tziakas DN, Kaski JC, Chalikias GK, Bomero C, Hatseras DI, Holt DW. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability. J Am Coll Cardiol. 2007. 49:2081–2089.

43. Uyuklu M, Meiselman HJ, Baskurt OK. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties. Clin Hemorheol Microcirc. 2007. 36:25–33.

44. Villa E, Rábano A, Albarrán OG, Ruilope LM, García-Robles R. Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs. Am J Hypertens. 1998. 11:844–851.

45. West KL, Fernandez ML. Guinea pigs as models to study the hypocholesterolemic effects of drugs. Cardiovasc Drug Rev. 2004. 22:55–70.

46. Zacco A, Togo J, Spence K, Furlong S, Piser T. HMG CoA reductase inhibitor protect cortical neurons from excitotoxicity. J Neurosci. 2003. 23:11104–11111.